Business
NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update
Product Revenue of $2.4 Million up 72% Year Over Year Successfully Completed 16 Trigeminal Neuralgia Cases to Date, With All Patients Reportedly Pain Free* Management to Host Conference Call Today at 8:30 a.m. Eastern Time EDEN PRAIRIE, MINN. - M...
About this update from Neuroone Medical Technologies Corporation
[{"type":"image","caption":"","headline":"NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update","size":{"original":{"width":140,"height":70,"url":"https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mO0.S9ZzO4sUF2xxFN6OXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwNQ--/https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4","width":140,"height":70},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/mO0.S9ZzO4sUF2xxFN6OXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwNQ--/https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4","width":140,"height":70}}},{"type":"text","content":"Product Revenue of $2.4 Million up 72% Year Over Year","length":53,"tagName":"p"},{"type":"text","content":"Successfully Completed 16 Trigeminal Neuralgia Cases to Date, With All Patients Reportedly Pain Free*","length":101,"tagName":"p"},{"type":"text","content":"Management to Host Conference Call Today at 8:30 a.m. Eastern Time","length":66,"tagName":"p"},{"type":"text","content":"EDEN PRAIRIE, MINN. - May 12, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and a business update for the second quarter of fiscal year 2026 ended March 31, 2026.","length":396,"tagName":"p"},{"type":"text","content":"Company Highlights","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Product revenue was $2.4M for the quarter, a 72% increase versus product revenue of $1.4 million in the second quarter of fiscal 2025.","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"To date, the Company successfully completed 16 cases using the OneRF(R) Trigeminal Nerve Ablation System for the treatment of facial pain known as trigeminal neuralgia, with all patients reportedly pain free after the procedure.*","length":229,"tagName":"p"}]},{"val":[{"type":"text","content":"A new high-net-worth investor acquired approximately 7.4% of NeuroOne's outstanding common stock in the open market.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"David Wambeke appointed Chief Busine...